RecruitingNeoplasm Malignant
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
Sponsor: Merck Sharp & Dohme LLC
You may qualify if…
- ✓ The main inclusion criteria include but are not limited to the following:
- ✓ Has locally advanced unresectable or metastatic solid tumor malignancy other than colorectal cancer and has progressed on, or following, standard of care systemic treatment
- ✓ Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation
You may not qualify if…
- ✕ The main exclusion criteria include but are not limited to the following:
- ✕ Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- ✕ Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- ✕ Has known active central nervous system metastases and/or carcinomatous meningitis and/or primary brain tumors
- ✕ Has active infection, other than those permitted per protocol, requiring systemic therapy
- ✕ Has not adequately recovered from major surgery or has ongoing surgical complications
Where it's recruiting
Source: ClinicalTrials.gov · NCT07209111 · last updated 2026-06-22